The Top Line cover image

AbbVie, ADCs and the future of cancer care

The Top Line

00:00

Intro

This chapter explores the evolution of cancer treatment strategies, with a particular focus on antibody drug conjugates (ADCs). It highlights AbbVie's shift towards solid tumors and the promising approval of their ADC, Amaryrelis, for non-small cell lung cancer.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app